Panel Discussion & Q&A: Using AI-Powered NASH Pathology to Accelerate NASH Drug Development: Where Are We Today & Where Are We Headed?
Time: 5:35 pm
day: Accelerating NASH Drug Development with AI-Powered NASH Pathology
- Discussing latest advancements of AI-powered pathology to address the most immediate issues with variability in CRN scoring for enrollment and endpoints to advance NASH drug development
- Tackling numerous challenges that impact trial success including inter-reader variability from manual reads, trial delays due to challenging patient enrollment, and additional costs or delays due to inconsistent performance of pathology operations
- Discovering how PathAI’s AI-powered measurement of NASH provides reproductible endpoint analysis and patient enrollment across the clinical development pipeline
Anne-Sophie Sejling, MD, PhD " alt=" Anne-Sophie Sejling, MD, PhD " itemprop="image">
Sophie Jeannin Megnien, MD " alt=" Sophie Jeannin Megnien, MD " itemprop="image">